[{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Taiho Oncology"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Cancer Research UK | UCL Cancer Trials Centre | Belgian Group of Digestive Oncology | National Cancer Institute, France | Taiho Oncology | Servier | Zymeworks | Accord healthcare | Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ Cancer Research UK | UCL Cancer Trials Centre | Belgian Group of Digestive Oncology | National Cancer Institute, France | Taiho Oncology | Servier | Zymeworks | Accord healthcare | Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Cancer Research UK | UCL Cancer Trials Centre | Belgian Group of Digestive Oncology | National Cancer Institute, France | Taiho Oncology | Servier | Zymeworks | Accord healthcare | Pierre Fabre"},{"orgOrder":0,"company":"National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"8","companyTruncated":"National Comprehensive Cancer Network \/ Taiho Oncology"},{"orgOrder":0,"company":"NCCN Oncology Research Program","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NCCN Oncology Research Program","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NCCN Oncology Research Program \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"NCCN Oncology Research Program \/ Taiho Oncology"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Onco360","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Taiho Oncology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Futibatinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Futibatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 18, 2024

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene ampli...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 18, 2023

                          Lead Product(s) : BBI-355,Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Taiho Oncology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Futibatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Esophageal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 14, 2023

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...

                          Product Name : Lytgobi

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 04, 2023

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : TAS-120 (futibatinib) is an oral, potent, selective, and irreversible tyrosine kinase inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarci...

                          Product Name : Lytgobi

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 27, 2023

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : TAS-120 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cholangiocarcinoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 14, 2023

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR. It has demonstrated anti-tumor activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations.

                          Product Name : Lytgobi

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 13, 2023

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...

                          Product Name : Lytgobi

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 18, 2023

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          UNICANCER

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          UNICANCER

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Cancer Research UK | UCL Cancer Trials Centre | Belgian Group of Digestive Oncology | National Cancer Institute, France | Taiho Oncology | Servier | Zymeworks | Accord healthcare | Pierre Fabre

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Futibatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Biliary Tract Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 14, 2022

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Cancer Research UK | UCL Cancer Trials Centre | Belgian Group of Digestive Oncology | National Cancer Institute, France | Taiho Oncology | Servier | Zymeworks | Accord healthcare | Pierre Fabre

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Futibatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 16, 2021

                          Lead Product(s) : Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank